Discovery of potent and selective Spleen Tyrosine Kinase inhibitors for the topical treatment of inflammatory skin disease.
Barker, M.D., Liddle, J., Atkinson, F.L., Wilson, D.M., Dickson, M.C., Ramirez-Molina, C., Lewis, H., Davis, R.P., Somers, D.O., Neu, M., Jones, E., Watson, R.(2018) Bioorg Med Chem Lett 28: 3458-3462
- PubMed: 30249354 
- DOI: https://doi.org/10.1016/j.bmcl.2018.09.022
- Primary Citation of Related Structures:  
6HM6, 6HM7 - PubMed Abstract: 
The discovery and lead optimisation of a novel series of SYK inhibitors is described. These were optimised for SYK potency and selectivity against Aurora B. Compounds were profiled in a human skin penetration study to identify a suitable candidate molecule for pre-clinical development. Compound 44 (GSK2646264) was selected for progression and is currently in Phase I clinical trials.
Organizational Affiliation: 
GlaxoSmithKline R&D, Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, UK. Electronic address: mike.d.barker@gsk.com.